I-Mab Zukünftiges Wachstum

NasdaqGM:IMAB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	7	-1,220	-639	N/A	3
12/31/2025	5	-1,060	-585	N/A	4
12/31/2024	5	-1,038	-551	N/A	4
12/31/2023	28	-1,466	-1,316	-1,305	N/A
9/30/2023	-113	-1,849	N/A	N/A	N/A
6/30/2023	-254	-2,138	N/A	N/A	N/A
3/31/2023	-238	-2,275	N/A	N/A	N/A
12/31/2022	-222	-2,507	-1,149	-1,103	N/A
9/30/2022	-50	-2,405	N/A	N/A	N/A
6/30/2022	122	-2,302	-1,146	-1,102	N/A
3/31/2022	105	-2,317	-1,075	-1,037	N/A
12/31/2021	88	-2,332	-1,003	-973	N/A
9/30/2021	1,596	-662	288	308	N/A
6/30/2021	1,560	-23	329	341	N/A
3/31/2021	1,552	224	377	387	N/A
12/31/2020	1,543	471	426	434	N/A
9/30/2020	N/A	-952	-811	-799	N/A
6/30/2020	15	-1,211	-839	-829	N/A
3/31/2020	23	-1,348	-860	-848	N/A
12/31/2019	30	-1,485	-880	-868	N/A
9/30/2019	40	-1,227	-790	-778	N/A
6/30/2019	47	-1,093	-618	-606	N/A
3/31/2019	51	-748	-457	-443	N/A
12/31/2018	54	-403	-295	-281	N/A
12/31/2017	12	-298	-272	-252	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IMAB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IMAB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IMAB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IMABDie Einnahmen des Unternehmens (29.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: IMABDie Einnahmen des Unternehmens (29.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IMAB in 3 Jahren voraussichtlich hoch sein wird

I-Mab Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to CN¥12.72 loss

Price target decreased by 17% to US$21.56

Consensus revenue estimates fall by 15%

Consensus revenue estimates fall by 78%

Price target decreased by 19% to US$24.47

Price target increased by 8.5% to US$27.65

Recent updates

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to CN¥12.72 loss

I-Mab: Trading Below Net Cash With Multiple Upside Options

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-Mab Announces Board Changes , Effective February 10, 2024

Member of Scientific Advisory Board notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Price target decreased by 17% to US$21.56

Chief Legal Officer notifies of intention to sell stock

I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy (PMN)

I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503

New minor risk - Share price stability

Consensus revenue estimates fall by 15%

Consensus revenue estimates fall by 78%

Price target decreased by 19% to US$24.47

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2023 Results on Aug 17, 2023

Member of Scientific Advisory Board notifies of intention to sell stock

I-Mab Announces the Appointment of Raj Kannan as Member of the Board of Directors

TRACON Pharmaceuticals, Inc. Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

Price target increased by 8.5% to US$27.65

Interim CFO notifies of intention to sell stock

Price target increased by 7.2% to US$27.30

Price target decreased by 11% to US$29.81

Price target decreased by 7.7% to US$33.57

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

Member of Scientific Advisory Board notifies of intention to sell stock

Price target decreased to US$36.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues miss analyst expectations

I-Mab Announces Management Changes

I-Mab Announces Executive Changes

I-Mab: Another CD47 Inhibitor Biotech With Great Potential

I-Mab(NasdaqGM:IMAB) dropped from FTSE All-World Index (USD)

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

Consensus revenue estimates fall by 63%

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

I-Mab to Report First Half, 2022 Results on Aug 30, 2022

Consensus revenue estimates fall by 13%

Price target decreased to US$58.94

I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1Bb Bispecific Antibody TJ-CD4B in Solid Tumors in China

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

I-Mab Valuation Offers A Biotech Investment Opportunity

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin Alfa for Treatment of Pediatric Growth Hormone Deficiency

Price target decreased to US$74.89

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat

I-Mab Reportedly Exploring Possible Sale Amid Takeover Interest

Consensus revenue estimates fall by 32%

Price target decreased to US$87.94

Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates

Founder notifies of intention to sell stock

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors

I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors

Chief Commercial Officer notifies of intention to sell stock

Director notifies of intention to sell stock